Melanoma Clinical Trials in Durham, North Carolina

6 studies are recruiting for melanoma in Durham, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

   This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the earl…

   Stage

   Not phased

   Ages

   40 to 75

   Site

   Durham VA Medical Center, Durham, North Carolina

   Locations

   745 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT05334069 on ClinicalTrials.gov

2. DESTINY-PANTUMOUR04

   This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world…

   Stage

   Not phased

   Ages

   18 to 130

   Site

   Research Site, Durham, North Carolina

   Locations

   18 in total

   Run by

   AstraZeneca

   See if you can join NCT07124000 on ClinicalTrials.gov

3. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

   This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Duke Health System, Durham, North Carolina

   Locations

   111 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT06246916 on ClinicalTrials.gov

4. A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy

   The purpose of this study is to determine the safety and feasibility of administering the Tetanus Diptheria Vaccine (Td) or Polio Boost Immunization (IPOL) to patients with metastatic melanoma who are receiving immune checkpoint inhibitor (IO) therapy per standard of care. Subjects will have the va…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Duke University Medical Center, Durham, North Carolina

   Run by

   Duke University

   See if you can join NCT05077137 on ClinicalTrials.gov

5. MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

   This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary efficacy of MEM-288 in patients with advanced solid tumors. Eligible sub…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Duke Cancer Institute, Durham, North Carolina

   Locations

   2 in total

   Run by

   Memgen, Inc.

   See if you can join NCT05076760 on ClinicalTrials.gov

6. Excision of Lymph Node Trial (EXCILYNT) (Mel69)

   The purpose of this study is to find out if removing only the cancerous lymph node (known as a lymph node excision) is effective at preventing cancer from coming back in the same area of the lymph node excision. The study team is also trying to find out the side effects of this type of surgery and …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Duke University Health System, Durham, North Carolina

   Locations

   7 in total

   Run by

   Craig L Slingluff, Jr

   See if you can join NCT05839912 on ClinicalTrials.gov